![](https://european-biotechnology.com/wp-content/uploads/2024/08/Amferia-plaster-1030x542.jpg)
Amferia partners with Biokema expanding into Switzerland
Swedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
Financial figures of the partnership were not disclosed, However, thepartnership with Biokema will enable Amferia’s technology to reach veterinary patients in Switzerland where wound care and infection prevention is of prime importance. With the growing threat of antibiotic-resistant infections globally, Amferia and Biokema’s partnership will build on extensive data collection and feedback from Amferia’s clinical testing across Europe, including Switzerland. The joint efforts aim at marketing the products starting early 2025.
Amferia‘s antimicrobial amphiphilic hydrogel kills bacteria, even resistant bacteria without harming the body. The material was developed through several years of research in collaboration with Chalmers University of Technology and the first product from this technology platform is a wound-care dressing for dry-to-low exuding wounds. Amferia’s anti-microbial solution can be used on wide-ranging wounds from simple skin injuries, post-operative wounds to chronic wounds and trauma / burn wounds.
The WHO warns that antibiotic-resistant infections, including those from wounds could become one of the leading causes of both illness and death over the next ten years, with India at the forefront of anti-microbial resistance (AMR). Amferia is committed to further research and development to expand the applications of its hydrogel technology. The company aims to improve infection control and patient outcomes across various medical fields. Today, Amferia has ongoing clinical studies in Europe and is seeking CE marking and FDA clearance for human application.
The company signed its first commercial agreement with Orkla Wound Care during Q2/2023. The proprietary material is being investigated for continuous development in several other areas, including sprays for deep wounds, and coatings for implants and a variety of catheters.